Please join us for the NRG Developmental Therapeutics meeting 12:30-2:30 pm in room Plaza AB . Pulmonologist Dr Powell will be providing great education on ADC induced lung disease. You won’t want to miss this!

Dr Banerjee kicked off #esmo2024 with a great talk on ADCs. Fcpeptide silencing to mitigate toxicity , different linkers, novel site specific conjugation technologies and another new developments ESMO - Eur. Oncology SGO

Starting the day off #ESMO2024 with excellent education on how technology can help clinical care . Whole genome sequencing has the ability to pick up additional mutations and can inform new and additional therapeutic options ESMO - Eur. Oncology SGO

avelumab + MTX was suggested as the new standard regimen for low risk GTD. Exciting >95% durable cure rate in stage 1-3, WHO score 1-6. ESMO - Eur. Oncology SGO #esmo2024

“The most exciting negative study” ! While there was no benefit of pembro added to adjuvant chemotherapy in endometrial cancer, in dMMR pembro decreased the risk of recurrence or death but 70% (HR 0.3) ⁦ESMO - Eur. Oncology⁩ ⁦SGO⁩ #esmo2024

no OS benefit with niraparib first line maintenance therapy, but survival almost 70 months in HRD! I’m so relieved: no detrimental effect on OS and significant PFS benefit. 3x higher post progression PARPi use may have contributed to lack of OS benefit. ESMO - Eur. Oncology SGO #ESMO24

Again no benefit of immunotherapy in ovarian cancer . the addition of nivolumab to rucaparib as maintenance therapy for front line ovarian cancer did not results in better survival and increased toxicity. ESMO - Eur. Oncology SGO #ESMO24

We have not been able to improve outcomes of PARP inhibitor maintenance in the second line. ICON9 shows no benefit of maintenance olaparib and cediranib over olaparib alone in platinum sensitive recurrent ovarian cancer and increased toxicity ESMO - Eur. Oncology SGO #ESMO2024 #ESMO24

Dr Antonio Gonzalez summarizes his his distillation of the PICOLLO results presented by Angeles Secord and Rina-S presented by Dr Elizabeth Lee on FRa targeting ADCs in platinum sensitive and resistant #ovarian cancer #ESMO24 ESMO - Eur. Oncology SGO #esmo2024

⁦Bhavana Pothuri⁩ and Dr Tom Herzog comment on long term overall survival with niraparib maintenance in the ovarian cancer PRIMA trial and pembro added to adjuvant chemotherapy in endometrial cancer #esmo2024 ⁦ESMO - Eur. Oncology⁩ ⁦SGO⁩ #esmo24

Drs. Colombo and Ray-Coquard share their thoughts on frontline PARP inhibitor maintenance for ovarian cancer and differences in overall survival and bevacizumab use . Is it study population, the drug, the combination, duration of treatment? #ESMO2024 ESMO - Eur. Oncology SGO

Platinum sensitivity does not apply in endometrial cancer. Platinum-free interval (PFI) is associated with response to next therapy but is NOT better for platinum versus no platinum treatment. @GynOncJnls . sciencedirect.com/science/articl…